More recently, genome‐wide CRISPR screening from three independent groups revealed the involvement of 7‐dehydrocholesterol reductase (DHCR7) in ferroptosis, leading to the identification of 7‐dehydrocholesterol (7‐DHC), an intermediate metabolite of cholesterol biosynthesis, as an endogenous anti‐ferroptotic metabolite particularly in cancer and organ ischemia–reperfusion injury (Freitas et al. 2024; Li et al. 2024; Yamada et al. 2024). The gene discussed is DHCR7; the disease is cancer.